Alternatives to L-dopa for initial treatment of Parkinson's disease (PD) should be considered for patients younger than 65-70 years. Nonmotor symptoms are very common in PD and include ...

The company plans to submit a new drug application for tavapadon to the US Food and Drug Administration next year.

Rates of Parkinson’s disease are rising for reasons which remain unclear, yet it remains an incurable illness. Right now, the main treatment available to patients is levodopa, a therapy which ...

The Michael J. Fox Foundation is dedicated to finding a cure for Parkinson's through research and development of improved therapies. FDA Approves New Treatment for Advanced Parkinson’s ...

Here's a case study. Dispelling the myths and misconceptions about Parkinson's disease is important as these can prevent patients from receiving effective treatment and caring for themselves.

The field of non-pharmacological interventions for the treatment of individuals with Parkinson's disease ... just beginning to be included in therapy guidelines. Developments that are highlighted ...

West Coast charity partner Parkinson’s WA yesterday launched a new publication, “Guidelines for Physiotherapy Practice in Caring for People with Parkinson’s Disease”, or the “Physio Manual” as it has ...

Clinical studies have revealed that rasagiline is associated with improved outcomes in patients with early Parkinson's disease ... patients may be more prone to treatment-emergent adverse ...

Intra-Cellular Therapies is developing Lenrispodun for the treatment of patients with Parkinson's Disease in a phase 2 study.

The researchers note that, "despite the similarities, patients with these diseases have a different prognosis and do not respond to levodopa, the main treatment for Parkinson's disease.